Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - June 2017


It is often challenging to accurately predict human in vivo clearance from in vitro intrinsic clearance data for poorly metabolised compounds. To address this issue, Cyprotex's parent company, Evotec, have developed a low clearance human hepatocyte stability assay. The method, which uses plated human hepatocytes and a gel overlay, evaluates intrinsic clearance over extended time periods. Using this approach the extrapolation from in vitro to in vivo human intrinsic clearance is significantly improved compared to standard short term suspension methods. You can find out more below.

An article has recently been published in ATLA which details insight into a new collaboration known as the Alliance for Human Relevant Science. Cyprotex are founding members of the Alliance and are committed to the development and promotion of human relevant methods in order to reduce reliance on animal testing. Find out how you can download the publication for free.

In May, Cyprotex scientists attended the NC3Rs/SPS regional meeting in the UK and presented a poster on our 3D organ-specific research in the area of cardiotoxicity, nephrotoxicity and DILI. Download the poster below.

From 26-29 June, Cyprotex will be exhibiting and presenting posters at the ISSX conference in Cologne. Arrange a meeting with one of our scientists at the event.

Finally, in December last year, Cyprotex became part of the Evotec Group. We would like to share with you some of the highlights from the Evotec Group as whole.

New low clearance hepatocyte stability assay

Cyprotex's parent company, Evotec, have recently introduced a low clearance hepatocyte stability assay to improve the prediction of human intrinsic clearance.

Find out more

Low clearance hepatocyte stability
The Alliance for Human Relevant Science - download the recent publication

Cyprotex are founding members of the Alliance for Human Relevant Science. Find out more about the Alliance by downloading a recent publication

Download the publication

Download publication
Latest research in 3D organ-specific models - download the poster

Learn more about out latest research in the field of 3D liver, kidney and cardiac models. Download our poster presented at the recent NC3Rs/SPS meeting in Coventry in the UK.

Download the poster

3D Microtissue
Meet us at ISSX Cologne

Cyprotex will be exhibiting and presenting at the ISSX conference in Cologne from 26-29 June 2017. Visit our booth #201 or arrange a meeting with one of our scientists.

Arrange a meeting

Meet with Cyprotex
Highlights from our parent company, Evotec

Learn more about Evotec's involvement in the NURTuRE consortium to research chronic kidney disease. Plus, get an update on recent successes in drug discovery collaborations with Sanofi and Bayer.

Learn more

EVP Global Head of Chemistry & Directeur General France recently presented a webinar on Medicinal Chemistry Excellence: Efficient and Innovative Solutions for Superior Pre-clinical Candidates.

Access recording

Evotec will be attending the World Congress for Inflammation in London from July 8th-12th, 2017.
Pre-arrange a meeting with our scientific experts.

Arrange a meeting

Learn more
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.